Clinical trial NCT03396757: The Artificial Kidney Initiation in Kidney Injury 2
Official title: The Artificial Kidney Initiation in Kidney Injury 2 A Multi-Centre, Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Replacement Therapy for Acute Kidney Injury in ICU
Keywords: Acute Kidney Injury
Critical Care
Renal Replacement Therapy
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2018-01-11
Enrollment: 768
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The timing of renal replacement therapy (RRT) in the context of severe acute kidney injury (AKI) is one the most debated issues in critical care medicine. The Artificial Kidney Initiation in Kidney Injury (AKIKI) was the first large prospective multicenter randomized trial published on this topic. This study (published in the New England Journal of Medicine, July 2017) showed no significant difference between an early and delayed RRT initiation strategy in term of mortality. Nearly 50% of patients escaped RRT in the delayed strategy and this strategy was associated with less catheter-related infections and faster renal function recovery. Two (serum urea concentration \>40 mmol/l and oliguria/anuria for more than 72 hours) of the 5 criteria which mandated RRT in the delayed strategy are still open to debate since they have never been shown to put patient at danger. To go further into our investigation of RRT criteria, the investigators designed a study that would compare the "delayed strategy" used in AKIKI that can now be considered as "standard" with another in which RRT is delayed for a longer period in the absence of a life-threatening complication (such as hyperkalemia or severe overload pulmonary edema).

Detailed description: The timing of renal replacement therapy (RRT) in the context of severe acute kidney injury (AKI) is one the most debated issues in critical care medicine. The Artificial Kidney Initiation in Kidney Injury (AKIKI) was the first large prospective multicenter randomized trial published on this topic. This study conducted by our team (published in the New England Journal of Medicine, July 2017) showed no significant difference between an early and delayed RRT initiation strategy in term of mortality. Nearly 50% of patients escaped RRT in the delayed strategy and this strategy was associated with less catheter-related infections and faster renal function recovery. Two (serum urea concentration \>40 mmol/l and oliguria/anuria for more than 72 hours) of the 5 criteria which mandated RRT in the delayed strategy are still open to debate since they have never been shown to put patient at danger. To go further into our investigation of RRT criteria,the investigators designed a study that would compare the "delayed strategy" used in AKIKI that can now be considered as "standard" with another in which RRT is delayed for a longer period in the absence of a potentially severe complication (such as hyperkalemia or severe overload pulmonary edema).

The AKIKI 2 study will be a prospective, multicenter, open-label, two-arm randomized trial.

The study will involve 2 stages (an observational stage and a randomization stage) At any time during these two stages, the occurrence of a potentially severe condition defined below will mandate strong consideration for immediate RRT initiation unless a medical treatment can very rapidly resolve the situation.

Criteria that mandate strong consideration for RRT initiation at any time during the 2 stages of the study

1. Serum potassium concentration \>6 mmol/l
2. Serum potassium concentration \>5.5 mmol/l persisting despite medical treatment
3. Arterial blood pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with a PaCO2 \>50 mmHg without possibility of increasing alveolar ventilation
4. Acute pulmonary edema due to fluid overload despite diuretic therapy leading to severe hypoxemia requiring oxygen flow rate \>5 l/min to maintain SpO2\>95% (oxygen saturation) or FiO2\>50% (inspired oxygen fraction) under invasive or non-invasive mechanical ventilation

   * Observational Stage: All patients receiving (or who have received for the present episode) intravenous catecholamines and/or invasive mechanical ventilation and presenting with AKI classification stage 3 of KDIGO classification \[defined by at least one of the following criteria: serum creatinine concentration of more than 4 mg/dl (354 µmol/liter) or greater than 3 times the baseline creatinine level, anuria (urine output of 100 ml/day or less) for more than 12 hours, oliguria (urine output below 0.3 ml/kg/h or below 500 ml/day) for more than 24 hours\] and who have no potentially severe condition mandating strong consideration for immediate RRT initiation as described above will be included in an observational study. Clinical and metabolic conditions will be closely monitored and RRT consideration will be mandatory if one or more of these conditions (see above) occurs.
   * Randomization stage: Patients presenting, either immediately after inclusion or during their follow-up in the observational study, one or both of following criteria: a serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours even in the absence of an above-mentioned potentially severe condition will be randomly allocated to one of the two study treatment arms. One arm is termed "standard strategy" (which was the delayed arm of AKIKI 1) and the other a "delayed RRT strategy".

"Standard strategy": RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of initiation will be recorded and RRT sessions will be performed until criteria for cessation are observed (see below).

"Delayed strategy": RRT will be initiated only if one or more of above-mentioned potentially severe situations (see "Criteria that mandate strong consideration for RRT initiation at any time") occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). As already explained, the physician in charge will be allowed to try a medical treatment of hyperkalemia, acidosis or pulmonary edema and the decision to start RRT or not will be taken by him, according to his usual practice. The duration of anuria will not constitute a criterion per se for RRT initiation. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the standard strategy, with special care to avoid dialysis disequilibrium syndrome.

The choice of RRT modality (intermittent or continuous technique) will be left at the study site discretion. Several RRT modalities can be used in the same patient, according to attending physician's indication. Duration of and interval between sessions, and device settings as well as modality of anticoagulation are left at the investigator's discretion. However, RRT will be prescribed and monitored according to national guidelines in order to ensure optimal efficacy of RRT.

In case of RRT initiation in a context of high serum urea concentration (\> 40 mmol/l), prevention of dialysis disequilibrium syndrome will be recommended. The management will be left at clinician's discretion and will include one or several of the following measures :

* Slow, gentle initial hemodialysis (dialysis time \<2 hours and low blood flow rate)
* Increasing dialysate sodium levels
* Administration of osmotically active substance by using a high-glucose-concentration dialysate or administering hypertonic glucose in the venous line of the dialyser during dialysis.

All study centers have extensive experience in both acute kidney injury management and RRT techniques.

Renal replacement therapy discontinuation will be contemplated when spontaneous diuresis \>500 ml/24h, and highly recommended if diuresis is \>1000 ml/24h without diuretic administration or \>2000 ml/24h, in patients receiving diuretics.

Renal replacement therapy cessation will be mandatory if diuresis (as defined above) is present and serum creatinine level decreases spontaneously.

If improvement of renal function is insufficient to achieve a spontaneous decrease in creatinine level and/or if diuresis becomes lower than 1000 ml/24h without diuretics (or lower than 2000 ml/24h under diuretics), RRT will be resumed.

Renal function recovery will be defined according to urine output as mentioned above and RRT cessation without need for resumption in the following 7 days.

RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study. The physician in charge will be allowed to try a medical treatment.) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). Patients will not receive RRT whatever the duration of anuria/oliguria if none of the above-mentioned indications for RRT is present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the "standard" RRT strategy, with special care to avoid dialysis disequilibrium syndrome.

The decision to initiate RRT in the "delayed strategy" arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice.

Eligibility criteria: Inclusion Criteria:

All of the following criteria must be fulfilled to be included in the observational study (first stage):

* Adults (\>18 years)
* Hospitalized in a study ICU.
* Evidence of acute kidney injury compatible with the diagnosis of acute tubular necrosis in a context of ischemic or toxic aggression and who receive (or received for the same episode) invasive mechanical ventilation and/or catecholamine infusion.
* Acute kidney injury stage 3 of KDIGO classification defined by at least one of the following criteria: serum creatinine concentration of more than 4 mg/dl (354 µmol/liter) or greater than 3 times the baseline creatinine level, anuria (urine output of 100 ml/day or less) for more than 12 hours, oliguria (urine output below 0.3 ml/kg/h or below 500 ml/day) for more than 24 hours.

To be randomized (randomization stage), supplemental criteria must be fulfilled. These criteria can appear either immediately after inclusion in the observational stage, or during the follow-up of the patient in the observational stage, in the absence of any non-inclusion criteria (listed below) at the time of randomization:

* Oliguria/anuria (urine output \<0.3 ml/kg/h or \<500 ml/day) for more than 72 hours or serum urea concentration comprised between 40 and 50 mmol/l.
* Affiliation to a social security regime

Exclusion Criteria:

* Severity criteria mandating immediate RRT initiation (Table 1)
* Serum urea level \> 50 mmol/l
* Severe chronic renal failure (defined by a creatinine clearance \< 30 ml/min)
* Patients with inclusion criteria already present for more than 24 hours (to avoid delayed inclusions)
* AKI caused by urinary tract obstruction or renal vessel obstruction or tumour lysis syndrome or thrombotic microangiopathy or acute glomerulopathy
* Poisoning by a dialyzable agent
* Child C liver cirrhosis
* Cardiac arrest without awakening
* Moribund state (patient likely to die within 24h)
* Patient having already received RRT for the current episode of AKI
* Renal transplant
* Treatment limitation (withholding or withdrawal)
* Previous inclusion in this study
* Subject deprived of freedom, subject under a legal protective measure
* Pregnant or breastfeeding woman

Primary outcomes:
measure: number of RRT-free days
timeFrame: Day 28 after randomization
Secondary outcomes:
measure: Hydration status (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Hydration status (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Hydration status (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Nutritional status (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Nutritional status (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Number of hemorrhages (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of thrombocytopenia (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of thrombosis of a large venous axis (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of hypophosphatemia (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of hyperkalemia (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of hypernatremia (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of cardiac rhythm disorders (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of pneumothorax (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of hemothorax (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of air embolism (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Number of arterio-venous fistulae (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of pericarditis (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of unexpected cardiac arrest (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of hypothermia (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Percentage of patients receiving RRT at least once in the " delayed" RRT strategy arm (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Number of RRT sessions (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Time between randomization and RRT initiation (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Time to RRT weaning (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Time to renal function recovery (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Total cost of RRT-related consumables (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Number of dialysis catheter-free day (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Rate of catheter-related bloodstream infection (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Barthel ADL (activity of daily living) index (randomization stage)
timeFrame: Day 60 after randomization
measure: Percentage of patients with a decisions to withhold or withdraw life support therapies (randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Duration of ICU stay (observational and randomization stage)
timeFrame: Limited to 60 days after randomization
measure: Duration of hospital stay (observational and randomization stage)
timeFrame: Limited to 60 days after randomization
measure: ICU mortality (observational and randomization stage)
timeFrame: Limited to 60 days after randomization
measure: Day 28 mortality (observational and randomization stage)
timeFrame: Day 28 after inclusion
measure: Day 60 mortality (observational and randomization stage)
timeFrame: Day 60 after inclusion
measure: Hospital mortality (observational and randomization stage)
timeFrame: Limited to 60 days after randomization
measure: Ventilator free-days (observational and randomization stage)
timeFrame: Day 28 after inclusion
measure: RRT indications (observational and randomization stage)
timeFrame: Day 28 after inclusion
measure: RRT modalities (observational and randomization stage)
timeFrame: Day 28 after inclusion
measure: Duration of RRT
timeFrame: Until ICU discharge or day 28 after randomization
measure: Time to renal function recovery (observational and randomization stage)
timeFrame: Until ICU discharge or day 28 after randomization
measure: Time to spontaneous decrease in creatinine
timeFrame: Until ICU discharge or day 28 after randomization
Other outcomes:
Locations:
city: Alès
country: France
facility: CH Alès
city: Amiens
country: France
facility: CHU Amiens
city: Avignon
country: France
facility: CH Avignon
city: Beaumont-sur-Oise
country: France
facility: Groupe Hospitalier Carnelle-Portes de l'Oise Site Beaumont / Oise
city: Belfort
country: France
facility: Hopital Nord Franche Comté - Belfort
city: Bobigny
country: France
facility: CHU Avicenne - APHP
city: Boulogne-Billancourt
country: France
facility: CHU Ambroise Paré - APHP
city: Bourg-en-Bresse
country: France
facility: CH Bourg en Bresse / Fleyriat
city: Béthune
country: France
facility: CH Béthune Beuvry - Germont et Gauthier
city: Clermont-Ferrand
country: France
facility: Gabriel Montpied - CHU Clermont Ferrand
city: Colombes
country: France
facility: CHU Louis Mourier - APHP
city: Corbeil-Essonnes
country: France
facility: CH Sud Francilien
city: Créteil
country: France
facility: CHU Henri Mondor - APHP
city: Dieppe
country: France
facility: CH Dieppe
city: Dijon
country: France
facility: Hôpital François Mitterand - CHU Dijon
city: La Roche Sur Yon
country: France
facility: CHD Vendée
city: Le Mans
country: France
facility: CH Le Mans
city: Lens
country: France
facility: CH Dr Schaffner - Lens
city: Lille
country: France
facility: Hôpital Roger Salengro / CHRU Lille
city: Lorient
country: France
facility: Centre Hospitalier Bretagne sud - Lorient
city: Lyon
country: France
facility: GH Edouard Herriot - Lyon
city: Marseille
country: France
facility: Hôpital Nord - Anesthésie Réa - APHM
city: Marseille
country: France
facility: Hôpital Nord - DRIS - APHM
city: Marseille
country: France
facility: La Timone - APHM
city: Metz
country: France
facility: Hopital de Mercy, CHR Metz-Thionville
city: Montpellier
country: France
facility: Hôpital Lapeyronie - CHU Montpellier
city: Montpellier
country: France
facility: Hôpital St Eloi - CHU Montpellier
city: Nantes
country: France
facility: Hotel Dieu - Anesthésie Réanimation - CHU Nantes
city: Nantes
country: France
facility: Hotel Dieu - Réanimation MIR - CHU Nantes
city: Nantes
country: France
facility: Hôpital Nord Laennec - CHU Nantes
city: Nîmes
country: France
facility: CHU Nimes - Caremeau
city: Paris
country: France
facility: Chu Hegp - Aphp
city: Paris
country: France
facility: CHU Pitiè Salpêtrière - Pneumologie et réanimation médicale - APHP
city: Paris
country: France
facility: CHU Pitié-Salpêtrière - Réanimation médicale - APHP
city: Pierre-Bénite
country: France
facility: CHU Lyon Sud
city: Poitiers
country: France
facility: CHU Poitiers
city: Pontoise
country: France
facility: CH René DUBOS
city: Rouen
country: France
facility: CHU Charles Nicolle
city: Saint-Étienne
country: France
facility: CHU Saint Etienne
city: Versailles
country: France
facility: CH André Mignot
city: Pointe-à-Pitre
country: Guadeloupe
facility: CHU pointe à Pitre / Abymes
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Didier DREYFUSS, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gaudry S, Hajage D, Martin-Lefevre L, Lebbah S, Louis G, Moschietto S, Titeca-Beauport D, Combe B, Pons B, de Prost N, Besset S, Combes A, Robine A, Beuzelin M, Badie J, Chevrel G, Bohe J, Coupez E, Chudeau N, Barbar S, Vinsonneau C, Forel JM, Thevenin D, Boulet E, Lakhal K, Aissaoui N, Grange S, Leone M, Lacave G, Nseir S, Poirson F, Mayaux J, Asehnoune K, Geri G, Klouche K, Thiery G, Argaud L, Rozec B, Cadoz C, Andreu P, Reignier J, Ricard JD, Quenot JP, Dreyfuss D. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet. 2021 Apr 3;397(10281):1293-1300. doi: 10.1016/S0140-6736(21)00350-0.
citation: Meraz-Munoz AY, Bagshaw SM, Wald R. Timing of kidney replacement therapy initiation in acute kidney injury. Curr Opin Nephrol Hypertens. 2021 May 1;30(3):332-338. doi: 10.1097/MNH.0000000000000707.
citation: Gaudry S, Hajage D, Martin-Lefevre L, Louis G, Moschietto S, Titeca-Beauport D, La Combe B, Pons B, de Prost N, Besset S, Combes A, Robine A, Beuzelin M, Badie J, Chevrel G, Reignier J, Bohe J, Coupez E, Chudeau N, Barbar S, Vinsonneau C, Forel JM, Thevenin D, Boulet E, Lakhal K, Aissaoui N, Grange S, Leone M, Lacave G, Nseir S, Poirson F, Mayaux J, Asehnoune K, Geri G, Klouche K, Thiery G, Argaud L, Ricard JD, Quenot JP, Dreyfuss D. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial. Trials. 2019 Dec 16;20(1):726. doi: 10.1186/s13063-019-3774-9.